Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program | ||
By: GlobeNewswire - 08 Mar 2024 | Back to overview list |
|
The competitive Department of Defense “Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Translational Research Award” will fund preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury (TBI) models SAN DIEGO, March 08, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”) announced today that its collaboration with The Roskamp Institute (“Roskamp”), aimed at developing novel therapies for TBI using Biosplice’s promising small molecule DYRK (dual-specificity tyrosine phosphorylation-regulated kinase) inhibitors has been selected for funding by the DoD office of the Congressionally Directed Medical Research Programs (CDMRP). As part of the collaboration, the DoD TBIPHRP Award will fund Roskamp to undertake preclinical development in their well characterized TBI models using Biosplice’s DYRK inhibitors. This translational work could lead to future clinical trials for TBI patients. The data from this collaboration are anticipated to inform the development of Biosplice’s DYRK inhibitor class in the treatment of degenerative neurological conditions, including various tauopathies. TBI, along with Alzheimer’s Disease, certain Frontotemporal Dementias and Amyotrophic Lateral Sclerosis (ALS) are in a class of neurological disorders characterized by an aggregation of harmful tau proteins. Because the DYRK protein plays a key role in the formation of harmful tau protein aggregates, Biosplice believes that its potent and selective DYRK inhibitors can potentially constitute effective, first-in-class therapies. “We are pleased to collaborate with Roskamp in this exciting research program endeavoring to address a great unmet need for effective therapies for TBI,” said Dr. Yusuf Yazici, Chief Medical Officer of Biosplice. “DoD’s selection of the Biosplice/Roskamp collaboration validates years of our industry-leading development of highly-selective DYRK inhibitors.” Erich Horsley, CFO and CBO of Biosplice, added, “Over the past 10 years, our team at Biosplice has considerably deepened its chemical and clinical expertise in selective inhibition of DYRK and CLK kinases. This collaboration with Roskamp will help accelerate the development of our novel neurology therapies, ranging from TBI to ALS to Alzheimer’s disease.” This award builds upon more than four years of scientific collaboration between Roskamp and Biosplice. Previous research conducted by Roskamp has demonstrated efficacy in TBI animal models with Biosplice’s first-generation DYRK inhibitors. About Roskamp: About Biosplice: Learn more at https://www.biosplice.com. Corporate Contact: |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |